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SINTESIS KOMPLEKS SCHIFF BES LOGAM KUMPULAN 10 YANG 
MENGANDUNGI ONN DAN ONS: PENCIRIAN SERTA AKTIVITI 
SITOTOKSISITI DAN ANTIBAKTERIA 
 
 
ABSTRAK 
Dua puluh satu ligan bes Schiff daripada terbitan salisildihida yang mempunyai 
amina heterosiklik, anilina dan karbotioamida telah disintesis. Ligan telah 
dikoordinasikan dengan logam peralihan Kumpulan 10 seperti Ni(II), Pd(II) dan Pt(II). 
Sebatian yang telah disintesis telah dicirikan dengan parameter fizikal seperti takat 
lebur dan analisis unsur bahan. Sebatian ini juga telah dicirikan dengan teknik 
spektroskopi, i.e. FTIR, 1H NMR, 13C NMR, dan UV-Vis. Kebanyakan struktur ligan 
telah ditentukan dengan analisis pembelauan sinar-X kristal tunggal. Ligan poli dentat 
yang mengandungi kumpulan ONS dan ONN dikoordinatkan melalui kumpulan 
nitrogen imina, oksigen fenolik dan sulfur tiolat untuk membentuk kompleks planar 
persegi. Ligan tersebut membentuk kompleks satah segiempat sama dan oktahedron 
dengan ion Ni(II). Kompleks gugusan satah segiempat sama dan tetra-palladat 
diperoleh melalui koordinasi kumpulan ONS bersama Pd(II). Kompleks dan kompleks 
makro telah diperoleh melalui koordinasi Pt(II) dengan ligan yang mengandungi 
kumpulan ONS. Aktiviti biologi telah dinilai untuk potensi antikanser terhadap tiga 
jenis sel kanser iaitu kanser payudara manusia (MCF-7), kanser serviks (Hela), dan 
kanser kolon (HCT 116). Kompleks logam telah mempamerkan aktiviti yang lebih 
tinggi berbanding ligan sahaja terhadap semua jenis sel. Di dalam kebanyakan siri, 
kompleks Ni(II) telah menunjukkan aktiviti yang lebih tinggi berbanding kompleks 
Pd(II) dan Pt(II). Di antara sebatian yang telah disintesis, aktiviti tertinggi telah 
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ditunjukkan oleh L7-Ni terhadap karsinoma kolorektal dengan IC50 = 7.90 ± 0.40 μM, 
sedangkan piawai cisplatin menunjukkan IC50 = 10.1 ± 1.00 µM. Beberapa kompleks 
menunjukkan aktiviti yang sama seperti ubat yang sedia ada. Pada umumnya, 
kompleks logam mempamerkan aktiviti yang lebih tinggi daripada ligan. Secara umum 
semua ligan didapati tidak toksik terhadap sel-sel normal manusia (sel endotelial 
manusia Ea.hy926). Beberapa kompleks logam didapati toksik kepada sel-sel manusia 
biasa, contohnya IC50 L2-Pt dan L3-Ni masing-masing adalah 16.30 ± 0.90 μM dan 
5.80 ± 0.10 μM. Potensi antibakteria beberapa ligan terpilih dan kompleksnya diuji 
untuk sifat antibakteria terhadap dua jenis bakteria, iaitu Escherichia coli (Gram-
negative, ATCC 25922), dan Staphylococcus aureus (Gram-positif, ATCC 12600) 
melalui kaedah penyebaran cakera menggunakan antibiotik piawai. Di antara ligan dan 
kompleks yang diuji, beberapa daripadanya didapati aktif terhadap bakteria. Walau 
bagaimanapun, kompleks logam menunjukkan aktiviti yang lebih tinggi daripada 
ligan. Secara umumnya, kompleks Ni(II) dan Pd(II) mempamerkan aktiviti yang lebih 
tinggi daripada kompleks Pt(II). 
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THE SYNTHESIS OF GROUP 10 METALS SCHIFF BASE COMPLEXES 
WITH ONN AND ONS GROUPS: CHARACTERIZATION AND THEIR 
CYTOTOXICITY AND ANTIBACTERIAL ACTIVITIES 
 
 
ABSTRACT 
Twenty-one Schiff base ligands of salicyldehyde derivatives with heterocyclic 
amine, aniline and carbothioamide were synthesized. The ligands were coordinated to 
Group 10 transition metals Ni(II), Pd(II) and Pt(II). The synthesized compounds were 
characterized with physical parameters such as melting point and elemental analysis. 
These compounds were further characterized with spectroscopic techniques, i.e. FTIR, 
1H NMR, 13C NMR, and UV-visible spectroscopy. The structure of most of the ligands 
were elucidated with single crystal X-ray diffraction analysis. The poly dentate ONS 
and ONN group containing ligands coordinated via imine nitrogen, phenolic oxygen 
and thiolate sulphur to form square planar complexes. The ligands form square planar 
and octahedral complexes with Ni(II). Square planar and tetra-palladate cluster 
complexes were obtained with Pd(II) with the ligands containing the ONS group. 
Square planar and macro complexes were obtained with Pt(II) and ONS group 
containing ligands. The biological activity was evaluated for their anticancer 
properties   against three human breast cancer (MCF-7), cervical cancer (Hela), and 
colon cancer (HCT 116) cell lines. The complexes exhibited higher activity than 
ligands on all the cell types. In most of the series the Ni(II) complexes showed higher 
activity than Pd(II) and Pt(II). The L7-Ni showed highest activity against colorectal 
carcinoma with IC50 = .90 ± 0.40 µM among the synthesized compounds, whereas 
standard cisplatin shows IC50 =10.1 ± 1.00 µM. A few of the complexes showed very 
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similar activity as standard existing drugs. Generally, the metal complexes exhibited 
higher activity than the ligands. In general all the ligands were found to be non-toxic 
to normal human cell line (human endothelial cell line Ea.hy926). Some metal 
complexes were found to be toxic to the normal human cell line, e.g. the IC50 of L2-Pt 
and L3-Ni is 16.30 ± 0.90 µM and 5.80 ± 0.10 µM respectively. The antibacterial 
activities of a few selective ligands and their complexes were tested for their 
antibacterial properties against two bacteria, i.e. Escherichia coli (Gram-negative, 
ATCC 25922), and Staphylococcus aureus (Gram-positive, ATCC 12600) via disc 
diffusion method using the standard antibiotic. Among the tested ligands and 
complexes a few of them were found active against bacteria. However, the metal 
complexes showed higher activity than ligands. Generally, the Ni(II) and Pd(II) 
complexes exhibited a higher activity than Pt(II) complexes. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Schiff Base Compounds 
Schiff base compounds are an important class of chemicals in this modern age 
of chemistry. Hugo Schiff was known as the first chemist who reported these 
compounds in 1864 [1]. Schiff bases are known as imines or azomethine compounds 
[1-5], generally having the formula R1R2C=NR3 (Scheme 1.1), whereas R1, R2 and R3 
are alkyl, aryl, hydrogen or heteroaryl groups [1, 5, 6].  The Schiff base compounds 
and their coordination complexes with transitional metals has played a significant role 
in coordination chemistry, polymer chemistry, material science, medicinal and 
industrial chemistry [7-11].  Azomethine compounds having important C=N linkage 
show potential antibacterial, anticancer, antifungal and antidiuretic activities [3, 12-
15].  
 
R1= R2 = R3= H, alkyl, aryl, heteroaryl, 
Scheme 1.1. The chemical reaction to show the synthesis of a Schiff base.  
 
1.2 N-heterocyclic Schiff base compounds 
Heterocyclic Schiff base compounds having heteroatoms S, N and O (Scheme 
1.2) show a wide variety of biological activity as well as show distinct chemical 
characteristics due to their diversity in bonding to transition metals [16-19]. Nitrogen 
and sulphur containing heterocyclic pyridine and thiazole moieties show potential 
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biological activities against hyperthyroidism, human immunodeficiency virus (HIV), 
fungal, prion disease and gram-positive and gram-negative bacteria [20-22]. 
Imidazoles are potential biomolecules which show interesting biological activities 
such as antimicrobial, anti-candida, anti-tumor, anti-cancer, anti-inflammatory, 
cytotoxicity and anti-cryptococcal, like histidine, histamine and purine amino acids 
[23-26]. 
 
Scheme 1.2. The structure of heterocyclic Schiff base compounds.  
1.3 Type of carbazone Schiff base compounds 
Schiff bases of isothiosemi-, thiosemi-, and semicarbazone (Scheme 1.3), have 
been well studied due to their wide biological application, particularly their anti-cancer 
and anti-bacteria activities [27-33]. The interest in Schiff bases gradually increased 
due to the presence of hard or soft Lewis bases atoms together in the same molecule. 
The thiosemicarbazone Schiff base compounds contain soft Lewis base such as 
sulphur and nitrogen coordinating atoms as well as the hard Lewis base, oxygen atom 
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[34]. These Schiff base compounds are of special interest because of their diversity in 
hard and soft Lewis base metal complexation with hard and soft coordinating sites 
NSO [34-39]. 
 
Scheme 1.3. The structure of different type of carbazones. 
1.3.1 Mono-thiosemicarbazone 
Mono-thiosemicarbazone (R1R2C2=N3-N2(H)-C1(=S)N1R3R4) 1 (Scheme 1.4) 
compounds have different subclasses, determined by the substituents R1, R2, R3 and 
R4. The compound which originated from aldehyde, i.e. one of two substituents of C2 
(R1, R2) is hydrogen and the substituents in N1 (R3, R4) both can be hydrogen or one 
hydrogen and secondly the alkyl or aryl.  
 
Scheme 1.4. The structure of thiosemicarbazone Schiff base compounds.  
 
1.3.2 Bis-thiosemicarbazones 
Bis-thiosemicarbazones are formed by connecting to separated 
thiosemicarbazones moieties connected via a ring or C-C bond, as shown in structures 
2 and 3, respectively (Scheme 1.5). These tetra-dentate ligands entrap metal inside to 
form square planar complexes [40-42]. The length of the C-C bond in the backbone 
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affects the stability of the complexes. The higher number of C-C bonds via alkylation 
or arylation allow to better fit metal ions inside of the ligand cavity [41]. These tetra 
dentate ligands and transition metal complexes exhibit promising anticancer and 
antibacterial activity [43].  
Scheme 1.5. Bis-thiosemicarbazone Schiff base compounds. 
1.4 Different molecular forms of thiosemicarbazones Schiff base compounds 
Thiosemicarbazone can exists as thione-thiol tautomers 1a-1b (Scheme 1.6) 
and both tautomers can coordinate to a metal centre. The anionic 1c forms (Scheme 
1.6) due to deprotonation of N2H (1a) or SH(1b) [43]. There are different bonding 
modes of neutral and anionic forms according to substituent and central metal ion [44, 
45]. 
 
Scheme 1.6. The possible molecular forms of thiosemicarbazones in a solution neutral 
thione (1a), neutral thiol (1b) and anionic (1c). 
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1.4.1 Bonding approach in neutral form 
The thiosemicarbazone ligand series (R1R2C2=N3-N2(H)-C1(=S)N1R3R4) are 
coordinated to metal in neutral form, 1a through the lone pair electrons of nitrogen 
atom (N3) and S-chelation with X-bridging (X = N or O).  The coordination occurs 
through only the S atom are also known as shown in 4-5 (Scheme 1.7) [46, 47] and the 
lone pair electrons of N3 and S-chelation in 6 [48] of N3 and S-chelation in 7 [47, 49]. 
The other bonding modes are via X, N3 and S chelation in 8 [50, 51] and X, N3 and S 
chelation with S-bridging in 9 [52].  X bridging mode with S, N3 and X chelation in 
10 (Scheme 1.7) are also observed [53].  
 
Scheme 1.7. The coordination and bridging modes of neutral thiosemicarbazones 
ligands to metals.  
 
 
1.4.2 Bonding approach in anionic form 
The thiosemicarbazone series (R1R2C2=N3-N2(H)-C1(=S)N1R3R4) in the 
anionic form 1c (Scheme 1.6) coordinate  in different modes with metals as shown in 
8-10 (Scheme 1.7) via N3, S-chelation and X-bridging as well as N3, S-chelation and 
S-bridging (where X = N or O). In the anionic form, the ligand will coordinate with 
metals via N2 and S chelation as shown in 11, whereas N2 and S chelation and S 
bridging in 12 (Scheme 1.8) [54-60].  
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Scheme 1.8. The coordination mode of anionic thiosemicarbazone ligands to metals.  
 
1.4.3 Bonding approach in bis-thiosemicarbazones 
The bis-thiosemicarbazones can coordinate either in the anionic or in the 
neutral form via both wings. The specific approach depends on the central ring; the 
connections are shown in 13 and 14 (Scheme 1.9) [61-63]. The bis-thiosemicarbazone 
undergoes deprotonation at the NH group and the tetra-dentate N2S2 subsequently 
coordinates to metal ions forming square planar complexes [64, 65]. The bis-
thiosemicarbazone chelating ligand form polynuclear complexes with different 
binding modes via N and S coordinating sites [66].    
 
Scheme 1.9. The coordination mode of bis-thiosemicarbazone ligands to metals. 
1.5 Transition metal complexes with thiosemicarbazone Schiff base 
 compounds 
Thiosemicarbazones having ONS coordinating sites are important in 
coordination chemistry due to their strong bonding ability with transition metals. These 
Schiff base compounds are of special interest because of their diversity in coordinating 
to hard and soft metals using the hard and soft coordinating sites. These compounds 
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and their complexes with transition metals have wide biological and pharmaceutical 
applications. 
 
1.5.1 Nickel complexes with thiosemicarbazone Schiff base compounds 
Schiff base containing thiosemicarbazone moieties and their metal complexes 
have significant interest because of their potential in biological activity [67]. The Ni(II) 
complexes with Schiff base ligands having dithiocarbazate moiety have been noted to 
exhibit strong activities against lymphocytic leukaemia [68]. The NS donor Schiff base 
ligand having thiodipropanoic acid and antipyrine moieties coordinated to Ni(II) have  
shown potential antifungal  and antibacterial activities [69]. The Ni(II) complexes with 
tetradentate N2O2 and tridentate N2O Schiff base ligands were significantly studied for 
catalytic and biological activity [70-72]. The Ni(II) complexes with (Z)-2-hydroxy-
Nˊ-(2-oxoindolin-3-ylidene) benzohydrazide and similar ligands have shown potential 
antimicrobial, antitumor and anti-cancer activities compared to the free ligand [13, 72, 
73]. The NSO coordinating site containing thiosemicarbazone ligand forming 
complexes with Ni(II) exhibit more antibacterial, anticancer and anticancer activity 
than the free ligand [74, 75]. 
 
1.5.2 Palladium Complexes with thiosemicarbazone Schiff base compounds 
The thiosemicarbazones and dithiocarbazide with N and S donor site are 
known as soft Lewis base, thus theoretically strongly coordinated with soft Lewis acid 
such as palladium Pd(II) [76, 77]. The Pd(II) is d8 metal ion, can form stable complexes 
with S containing thiosemicarbazone ligand due to strong σ-bond and dΠ- dΠ bonds by 
the donation of an electron pair to the ligand [30]. These Pd(II) complexes are more 
potent against virus such as malaria, tumour, cancer cells, bacteria, and fungi by 
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inhibiting their ribonucleotide and transforming it to the deoxy-ribonucleotide [77-79]. 
Square planar complexes of palladium with Schiff base containing nitrogen and 
oxygen/sulphur coordinating sites are very important systems on account of their 
anticancer, catalytic and antitumor activities  [80]. The Pd(II) complexes with nitrogen 
containing pyridine, quinoline, derivatives ligands shown promising anticancer and 
antitumor activity [81]. The trans-palladium(II) quinolylmethyl phosphonate 
complexes which exhibit potential in vitro anti-tumour activity [82]. The Pd(II) 
complexes of S-alkylthiosemicarbazone and thiosemi carbazone exhibited promising 
activity against bacteria such as Candida albicans, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Staphylococcus aureus, Proteus mirabilis, Escherichia coli 
[83]. The NSO tridentate and NS bidentate thiosemicarbazone complexes with Pd(II) 
exhibited significant anticancer antibacterial, antifungal and antibacterial activity [76, 
84, 85].    
  
1.5.3 Platinum complexes with thiosemicarbazone Schiff base compounds 
Cisplatin was synthesized by Pyrone in 1844 and was permitted for the 
treatment against human cancer in 1978. However, the biological effect of this 
compound on cancer was accidentally discovered by Rosenberg and co-workers in 
1965. The emergence of modern medicinal chemistry, which was inspired by the 
discovery of cisplatin, has been contributed by the extensive knowledge and efforts of 
medicinal chemists on the coordination and biological properties of metal ions. The 
thiosemicarbazone moiety containing Schiff base ligands chelate with Pt(II) shows 
higher activity against antitumor and anticancer than their ligands; while metal-based 
drugs are more promising and convenient as therapeutic agent [86-89]. The complexes 
of Pt(II) with 4(N)- substituted derivatives of 2-acetylpyridine thiosemicarbazone 
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exhibited potential antitumor, anticancer, antibacterial, antineoplastic and cytogenetic 
activities [88, 90, 91]. The NS coordinating site containing carbazate chelated to Pt(II) 
exhibits potential antibacterial and anticancer activity [92]. 
1.6 Antiproliferative activities of transition metal complexes of Schiff base 
 compounds 
Cancer is a deadly disease occurring both in male and female across the world. 
Almost half of all male and one-third of all female are diagnosed with cancer [93]. It 
is identified that one-quarter of adults’ mortality is because of cancer [94]. However, 
cancer treatment is a massive task for oncologists to get feasible remedy with 
reasonable cost. Nowadays, many drugs are generally available to treat breast cancer, 
cervical and colon cancer such as Tamoxifen, 5-fluorouracil (5-FU) and Bevacizumab. 
However, these chemotherapeutic drugs are often less effective and sometimes cancer 
cells may exhibit or develop resistance to these drugs [95].  It was observed that DNA 
is one of the primary intracellular targets for anti-cancer drugs. It is thus important to 
understand the different binding modes of these small molecules towards DNA. The 
recognised noncovalent binding modes of small molecules to DNA are intercalative 
binding, groove binding and external electrostatic binding [96, 97]. 
Thiosemicarbazones Schiff base complexes with Cu(II) and hydrazine with Mn(II) 
exhibit potential antitumor and anticancer activity [98-101]. The tetradentate N2O2 
Schiff bases complexes with Pt(II) and Pt(IV) exhibit promising anticancer activity 
[102] while the Cu(II) complexes of bidentate N2 Schiff base exhibit affordable 
anticancer and antitumor activity [103]. 
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1.7 Anti-bacterial activities of Nickel, Palladium and Platinum complexes 
 with thiosemicarbazone Schiff base  
Most of the Schiff bases have been shown to have a wide range of biological 
activities attributed to the –HC=N- imine functional group [104-107]. Biological 
activities have been shown to take place through hydrogen bonding (Fig. 1.8) of the 
imine of Schiff bases to the active site of the cell [108]. 
 Metal coordinated Schiff base compounds are more effective in biological 
activity than uncoordinated ligands [109-111]. Thiosemicarbazones Schiff bases show 
uncommon coordination due to two factors. The factors responsible for uncommon 
coordination are: (a) intramolecular hydrogen bonding which reduces the ability of 
bonding of the lone pair electrons of the imine nitrogen; and (b) the bulky group on 
the chelating ligand (Scheme 1.10) [112].  
 
Scheme 1.10. The possible bonding to metal and hydrogen bonding. 
Transition metal complexes containing nitrogen, oxygen and sulphur donor 
sites possess unique configuration, structural lability and show biocidal activities 
[113]. The environment around the metal centre such as its coordination geometry, 
coordinated site and donor group are the key point for biological activities [114]. 
Thiosemicarbazone derivatives coordinated to metal ion forming chelates arise 
biological activities. The lipophilicity of the compounds regulates the access of 
constituents into the cell [115-117]. The peptidoglycan cell membrane of  gram-
positive bacteria  is thicker than gram-negative bacteria, therefore Minimum Inhibition 
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Concentration (MIC) can be more for gram-positive  bacteria than  gram- negative 
bacteria due to different rate of the inoculation of compound diffusion [118].   
The Pd(II) complexes with Schiff base derived from dithiocarbazic acids show 
potential biological activities due to their kinetic lability and thermodynamic stability 
[68, 119]. Nowadays, dangerous life-threatening contagious diseases initiated by multi 
- drug resistant Gram-positive and Gram-negative bacteria have been detected in 
alarming levels throughout the world [120]. Thiosemicarbazones, and nitrogen and 
sulphur containing chelating agents are becoming highly important in coordination 
chemistry and biology due to their physico-chemical properties and pharmacological 
properties [92, 121, 122]. 
1.8 Heterocyclic and thiosemicarbazone Schiff base compounds and their 
complexes 
Thiosemicarbazones, particularly (R1R2C2=N3-N2(H)-C1(=S)N1R3R4) are very 
important compounds with S and N coordinating centres; their coordination chemistry 
was firstly noted in the early sixties [123]. Ali and  Livingstone [30] initially studied 
the chemistry of thiosemicarbazone  which was successfully reviewed in 1975 by 
Campbell [28]. Patil and Shah in 1980 and subsequently Dave and Thampy in 1981 
had reported the square planar Ni(II) complexes (Scheme 1.11) with 2-
hydroxyacetophenone and its substituted derivatives thiosemicarbazone [124, 125]. 
 
Scheme 1.11. The square planar Ni(II) complexes of thiosemicarbazone Schiff base 
ligands.  
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 Metal-thiosemicarbazone coordination chemistry was studied in 1985 by 
Padhye and Kauffman [45], later by West et al in 1991 and 1993 [121, 126]. The Pd(II) 
and Pt(II) tetranuclear complexes with p-isopropylbenzaldehyde thiosemicarbazone 
was reported by Quiroga and Pérez in 1998 [79]. Further studies in this area was 
carried out by Casas et al in 1999 and 2000 [127, 128]. The reaction mixture of 
thiosemicarbazide and aldehyde or ketone was refluxed in methanol and in the 
presence of molecular sieves to synthesize thiosemicarbazone Schiff base compounds 
[43].  
The synthesis of first row transition metal complexes with thiosemicarbazone 
were basically prepared from metal acetates, sulphates, perchlorates, halides or nitrates 
in organic solvent at room temperature or at refluxing temperatures [54, 129-137]. The 
complexes with 4d and 5d transition metals with thiosemicarbazone were prepared by 
different routes depending on the type of metals. The Pd(II) and Pt(II) complexes were 
synthesized using M2PdCl4 and M2PtCl4 (M = Li, K) [54, 87, 138-142]. 
Ni(II) form different types of complexes which are mononuclear and 
polynuclear with Schiff base chelating ligand was reported by Leovac et al in 2007 
and Suni et al in 2007 [32, 143]. The Ni(II) is usually observed to coordinate with 
anionic bidentate or tridentate ligand via S or O donor site.  The Ni(II) forms square 
planar complexes where the fourth position was occupied with NCS (N-bonding), Br, 
Cl, MeCO2, PPh3, and NH3, while the thiosemicarbazone ligand was tridentate in the 
complexes 15-20 (Scheme 1.12) [144-150].  
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Scheme 1.12. The synthesized complexes of thiosemicarbazone Schiff base ligand to 
nickel.  
 
The N3 and S coordinating site containing thiosemicarbazone form trans square 
planer [PdL2] complexes, 21-24 of Pd(II) (Scheme 1.13) [151-154]. At the same time 
Vila and Pereira reported the square planar [PdL2]·CHCl3 25 (Scheme 1.13) complex 
with cis-position of S-donor site [155]. 
 
Scheme 1.13. The synthesized complexes of thiosemicarbazone Schiff base ligand to 
palladium.  
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Thiosemicarbazone uninegative tridentate NNS coordinating sites ligand form 
Pt(II) complexes with general formulae of [PtLY], shown as 26-30 (Scheme 1.14), 
whereas X = N or P [88, 90, 139, 142, 156]. The dinegative tridentate ONS 
coordinating site and the same ligand as neutral monodentate via S coordinating site 
form square planar Pt(II) complex, [PtL(H2L)]  31, whereas X = O [157].  
 
Scheme 1.14. The synthesized complexes of thiosemicarbazones Schiff base ligand to 
platinum.  
1.9 Anticancer and antibacterial activities of thiosemicarbazone and 
hydrazone Schiff base compounds and their complexes 
The interest of Schiff base and its complexes with transition metals is 
increasing due to potential biological application [158]. Brockman and Thomson in 
1956 had investigated the anti-leukemic activity of pyridine-2-carbaldehyde 
thiosemicarbazone but the compound was found to be toxic [159]. Antholine and 
Knight in 1976 reported the potential antitumor activity of iron and copper complexes 
of 5-substituted-2-formylpyridine thiosemicarbazones against tumor cell lines [160]. 
Dobek and Klayman in 1986 reported the remarkable antibacterial activity of 2-
acetylpyridine-1-oxide thiosemicarbazones against N. gonorrhoea, S. faecalis, N. 
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meningitis and S. aureus  [161]. Liu and Lin in 1992 observed the antitumor activity 
of  3- and 5-aminopyridine-2-carboxaldehyde thiosemicarbazones on L1210 
leukaemia, whereas the 3-amino substituted complex was found to be more active 
[162]. Oxovanadium(IV) complexes of thiosemicarbazone of 2-formylpyridine 
showed potential in vitro activity against E. coli was reported by Maiti and Guha in 
1988  [163]. The titanium and zirconium complexes of thiosemicarbazone derived 
from 2-acytylnaphtalene, 2-acytylthiopene, 2-acytylpyridine, and 2-acytylfuran 
exhibited potential activity against E. coli, S. aureus, S. viridans and P. mirabilis [164]. 
3-aminopyridine-2-carboxaldehyde thiosemicarbazone has been shown to have 
potential activity against mouse M109 lung carcinoma and A2780 human ovarian 
carcinoma [165]. Bindu et al. in 1998 investigated antibacterial activity against 
pathogenic bacteria of human Salmonella typhi, S. aureus and, Shigella dysentariae 
using Cu(II) complexes of N-phenylsalicylaldehyde thiosemicarbazone, where they 
found that the complexes exhibited higher activity than the ligand  [166]. Küçükgüzel 
et al in 1999 [167] studied the antibacterial activity against Staphylococcus aureus 
using ethyl-2-arylhydrazone-3-oxobytyrates derivatives. Kovala and Yadav in 2000 
synthesized Pt(II) square planar complexes with 2-acetylpyridine thiosemicarbazone-
N-Me [PtLCl] and tested against sophisticated ovarian cancer cell lines A2780/Cp8 
and A2780. The IC50 values of 0.14 and 0.08 µM obtained respectively was higher 
than cisplatin [88]. Kovala and Demertzi in 2001 and 2003 studied the square planar 
and distorted square planar complexes of Pt(II) with thiosemicarbazone that exhibit 
lethal effect against Gram (+) bacteria [87, 90]. Singh and Narang  [168] carried out 
the study on antibacterial activity against Escherichia coli as well Aspergillus niger 
using Co(II), Ni(II), Zn(II), Cu(II) and Cd(II) complexes with acetophenone-4-
aminobenzoylhydrazone and 4-hydroxyacetophenone-4-aminobenzoylhydrazone. 
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Savini and Chiasserini in 2004  [169]  had reported the anticancer activity of 3- and 5-
methylthiophene-2-carboxaldehyde α-(N)-heterocyclic hydrazone derivatives. 6-
Methyl-2-formyl pyridine Schiff bases of S-methyldithiocarbazates ligand (Hmpasme) 
form complexes [Pd(mpasme)Cl], [Pt(mpasme)Cl] and [Pt(Hmpasme)Cl] with (Pd(II) 
and Pt(II) respectively and were investigated against human ovarian cancer (Caov-3) 
cell lines. The ligand and platinum complex showed remarkable activity but Pd(II) 
complex showed only weak activity was reported by Ali et al in 2006 [170]. Al-
Sha’alan in 2007  [171] evaluated the antibacterial activity against Staphylococcus 
aureus and Escherichia coli using Cu(II), Ni(II), Co(II), Mn(II) and Fe(II) complexes 
with 7-chloro-4-(benzylidenehydrazo) quinolone. Pyridyl thiosemicarbazone and its 
transition metal complexes were tested   for anti-bacterial activities. The higher 
inhibitory effect was found for complexes because of  more lipophilicity of complexes 
than ligand [43]. The Pd(II) and Pt(II) complexes of 2-acetyl-4-methylthiazo 
lethiosemi carbazone and 2-acetylpyrazinethiosemicarbazone exhibited potential 
activity against two human tumor cell lines HT-29 and  HuTu-80  were reported in 
2016 by Nimir et al [172]. Pt(II) complexes of methylhydrazine carbodithioate 
derivatives of indolin-2-one exhibited strong activity against HCT 116, MCF-7 was 
reported by Li et al in 2017  [173].  
 
1.10 The Problem statement 
The thiosemicarbazone and heterocyclic Schiff base compounds are important 
segment for chemistry, biology and medicinal chemistry. These compounds were 
synthesized by different techniques which gave low yield [174-176]. These 
compounds contain nitrogen, sulphur and oxygen together in the same molecule. The 
ONS and ONN group could be chelated strongly with transition metal ions. Very few 
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of these compounds have been reported complexed to group 10 transition metal ions 
in the literature. The percentage yield was not satisfactory and the synthetic procedures 
were not described explicitly.    
These compounds and their transition metal complexes might have good 
biological and medicinal properties. Cis-platin was the first group 10 metal chelated 
complex to be used as an anti-cancer agent. It has been identified that the nitrogen 
moiety in cis-platin plays an important role in its anti-cancer activity. Similar 
complexes as cis-platin could be a potential chemotherapeutic agent for cancer 
treatment besides surgery and radiation therapy. Therefore, the comparative 
investigation against cancer cell lines using thiosemicarbazone and heterocyclic Schiff 
base ligands and their complexes with Group 10 metal ions, seems to be an interesting 
option to be investigated. 
Dangerous life-threatening contagious diseases initiated by multi-drug 
resistant gram-positive and gram-negative bacteria have been increasing at an alarming 
rate across the world. Thiosemicarbazones, particularly nitrogen and sulphur 
containing chelating agents have shown promising activities against such bacteria. In 
addition, the phenolic OH containing groups have shown potential antibacterial and 
antifungal activities [177, 178]. From the literature review the Schiff base ligands and 
their complexes with Group 10 metal ions have not been investigated comparatively 
against gram-positive and gram-negative bacteria. These compounds could be the 
potential agent against diseases originating from microorganism. 
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1.11 Objective of the research work 
In this work, some new Schiff base compounds will be synthesized and 
complexed with group 10 transition metal ions. These complexes and their ligands will 
be subjected to the characterization and cytotoxicity and bacteriological studies. The 
specific objectives to fulfil the aim of this study are as follows:  
1. To synthesize and fully characterize thiosemicarbazone, heterocyclic and 
oxygen bis Schiff base compounds having ONS and ONN coordination sites. 
2. To synthesize and fully characterize the Ni(II), Pd(II) and Pt(II) complexes 
with the above Schiff base ligands. 
3. To evaluate of their anti-proliferative activities against breast cancer (MCF-7), 
colon cancer (HCT 116), cervical cancer (Hela) and normal (endothelial cell 
Ea.hy926) cell lines. 
4. To test of their antibacterial activities against gram-positive Staphylococcus 
aureus and gram-negative Escherichia coli.  
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CHAPTER TWO 
EXPERIMENTAL 
 
2.1 Material and measurement 
All the reagents and chemicals were purchased from Sigma-Aldrich and Fluka. 
The solvents were purified with prescribed standard procedure  [179]. FTIR data were 
obtained using the Perkin Elmer System 2000 FTIR as KBr disc in the range 400-4000 
cm-1. The melting points were recorded using a Gallenkamp melting point apparatus 
(model 7936B, England). The 1H and 13C NMR were recorded with Bruker Avance III 
500 MHz and 125 MHz spectrophotometer respectively using TMS as internal 
standard and DMSO-d6, CD3OD-d4, OC(CD3)2-d6, and CDCl3 as solvent. X-ray 
crystallographic data were recorded on a Bruker SMART APEXII CCD area-detector 
diffractometer using graphite-monochromated MoKα radiation (λ = 0.71073Å) in the 
range 100 K to 294 K. The data were collected and reduced using APEX2 and SAINT. 
The structures were solved using the SHELXS-97 program package, and refined using 
the SHELXL-97 program package. All none hydrogen atoms were anisotropically 
refined. Molecular graphics were created using SHELXTL-97.   
 
2.2 Experimental procedure for the ligands synthesis 
2.2.1 General procedure for the synthesis of Schiff base ligands 
The aldehyde was dissolved in requisite amount of methanol or ethanol (20.0 
mL) and 0.20 mL glacial acetic acid was added as catalyst [49, 90-91, 179]. The 
corresponding amine was dissolved in methanol or ethanol then added to the aldehyde 
solution. The resulting solution was refluxed for 4 h, in a round bottomed flask 
equipped with magnetic stirrer and water condenser. The product was dried under 
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reduced pressure then washed with the appropriate solvent. The product was 
recrystallized with slow evaporation of solvent at room temperature and diffusion 
technique.  
 
 
Scheme 2.1. Synthesis of Schiff base ligands. The scheme shows the reaction between 
benzaldehyde derivatives and carbothioamide derivatives. 
  
Table 2.1. Ligand labels and their identity for compounds in Scheme 2.1. 
Sample 
Code 
R1 R2 R3 R4 R7 
L1 OH CH3 H H CH3 
L2 OH CH3 H H C6H11 
L3 OH NO2 H OCH3 C6H11 
L4 OH NO2 H OCH3 CH3 
L5 OH t-butyl H H C6H11 
L6 OH H H t-butyl C6H11 
L7 H OH OCH3 H C6H11 
L8 OH H OH H CH3 
L9 OH H H H C6H11 
L10 H OH OCH3 H CH3 
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Scheme 2.2. Synthesis of Schiff base ligands. The scheme shows the reaction between 
benzaldehyde derivatives and pyridine derivatives. 
 
Table 2.2.  Ligand labels and their identity for compounds in Scheme 2.2. 
Sample Code R1 R2 R3 R4 R5 R6 
L11 OH H H CH3 H CH3 
L12 OH H H CH3 CH3 H 
L13 OH CH3 H H CH3 H 
L14 OH CH3 H H H CH3 
L15 OH H H OCH3 H CH3 
L16 H OH OCH3 H CH3 H 
 
 
    
Scheme 2.3. Synthesis of Schiff base ligands. The scheme shows the reaction between 
benzaldehyde derivatives and imidazole derivatives. 
 
Table 2.3. Ligand labels and their identity for compounds in Scheme 2.3.  
Sample Code  R1 R2 R3 R4 E 
L17 H OH OCH3 H N 
L18 H OH OCH3 H S 
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Scheme 2.4. Synthesis of Schiff base ligands. The scheme shows the reaction between 
benzaldehyde derivatives and 4,4'-oxydianiline. 
 
Table 2.4. Ligand labels and their identity for compounds in Scheme 2.4.  
Sample Code  R1 R2 R3 R4 
L19 OH NO2 H OCH3 
L20 OH CH3 H H 
L21 H OH OCH3 H 
 
 
2.2.2 Synthesis of 2-(2-hydroxy-3-methylbenzylidene)-N-methyl 
hydrazine-1-carbothioamide (L1) 
The 0.68 g (5.00 mmol) 2-hydroxy-3-methylbenzaldehyde was dissolved in 
20.0 mL methanol, 0.20 mL glacial acetic acid was added and the mixture was refluxed 
for 30 minutes. A solution of 0.52 g (5.00 mmol) N-methyl hydrazinecarbothioamide 
in 20.0 mL methanol was added dropwise with stirring to the aldehyde solution. The 
resulting colourless solution was heated under reflux for 4 h with stirring. The crude 
product was washed with 5.0 mL n-hexane. The recovered product was dissolved in 
DMSO for purifying and recrystallization. Light yellow coloured single crystals 
suitable for X-ray diffraction study was obtained by slow evaporation of the solvent. 
Colour: Light yellow; M. P.: 181-182 oC; Yield (%): 94. anal. Cal. For C10H13N3OS 
(FW: 223.29 g mol-1); C, 53.74; H, 5.83; N, 18.81; Found: C, 53.71; H, 5.79; N, 18.83 
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%. 1H NMR (500 MHz, DMSO-d6, Me4Si ppm): δ 11.38 (s, N-NH), δ 9.39 (s, OH), δ 
8.34 (s, HC=N), δ 8.44 (q, CS-NH), δ 7.42-6.81 (multiplet, aromatic), δ 3.00 (d, J = 
4.5 Hz, N-CH3), δ 2.20 (s, Ph-CH3). The 13C NMR (DMSO-d6, Me4Si ppm): δ 177.48 
(C=S), δ 154.24 (C=N), δ 143.64-119.10 (C-aromatic), δ 31.05 (N-CH3), δ 15.91(Ph-
CH3) ppm. IR (KBr pellets υmax/cm-1): 3418 υ(NH), 3133 υ(OH), 2983(NC-H3, sp3), 
1618 υ(C=N), 1553 υ(C=C, aromatic), 1270 υ(C=S),  1251 υ(CH, bend., aromatic), 
1085 υ(C-O). 1043 υ(C-N). 
 
2.2.3 Synthesis of N-cyclohexyl-2-(2-hydroxy-3-methylbenzylidene) 
hydrazine -1 -carbothioamide (L2) 
The 0.68 g (5.00 mmol) 2-hydroxy-3-methylbenzaldehyde was dissolved in 
20.0 mL methanol. 0.20 mL glacial acetic acid was added to the mixture and was 
refluxed for 30 minutes. A solution of 0.87 g (5.00 mmol) N-cyclohexylhydrazine 
carbothioamide in 20.0 mL methanol was added drop wise with stirring to the aldehyde 
solution. The resulting colourless solution was refluxed for 4 h with stirring. The 
colourless precipitate was obtained with evaporation of solvent.  The crude product 
was washed with 5.0 ml n-hexane. The recovered product was dissolved in acetonitrile 
and purified by recrystallization. A colourless single crystals suitable for X-ray 
diffraction was recovered with slow evaporation of acetonitrile. M. P.: 240-241 oC; 
Yield (%): 93. anal. Cal. For C15H21N3OS (FW: 291.41 g mol
-1); C, 61.77; H, 7.21; N, 
14.42; Found: C, 61.81; H, 7.19; N, 14.42 %. 1H NMR (500 MHz, DMSO-d6, Me4Si 
ppm): δ 11.27 (s, N-NH), δ 9.51 (s, OH), δ 8.34 (s, HC=N), δ 8.05 (d, J = 8.35 Hz, 
CS=NH), δ 7.39-6.81 (multiplet, aromatic-H), δ 2.20 (s, Ph-CH3), δ 1.87-1.14 
(multiplet, cyclohexyl-H) ppm.  The 13C NMR (DMSO-d6, Me4Si ppm): δ 175.79 
(C=S), δ 154.29 (C=N), δ 143.76-119.17 (C-aromatic), δ 15.93(CH3), δ 52.87-
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24.90(C-cyclohexyl) ppm. IR (KBr pellets υmax/cm-1): 3364 υ(NH), 3148 υ(OH), 
2989(CH3), 2931 and 2854 υ(CH, cyclohexyl), 1620 υ(C=N), 1540 υ(C=C, aromatic), 
1268 υ(C=S),  1218 υ(CH, bend., aromatic), 1122 υ(C-O). 1075 υ(C-N). 
2.2.4 (E)-N-cyclohexyl-2-(2-hydroxy-5-methoxy-3-nitrobenzylidene)hydrazine-
1-carbothioamide (L3) 
The 2-hydroxy-5-methoxy-3-nitrobenzaldehyde 0.76 g (5.00 mmol) was 
dissolved in 20.0 mL methanol, 0.20 mL glacial acetic acid was added and the mixture 
was refluxed for 30 minutes. N-cyclohexylhydrazinecarbothioamide 0.54 g (5.00 
mmol) solution in 20.0 mL methanol was added dropwise with stirring to the aldehyde 
solution. The resulting deep orange solution was refluxed for 4 h with stirring. A 
reddish orange precipitate was formed. The precipitate was filtered and washed with 
5.0 mL hot methanol and 5.0 mL n-hexane. The recovered product was dissolved in a 
mixture of THF and toluene (4:1) to attempt purification by recrystallization. Only a 
reddish orange solid product was isolated. The product was washed with 5.0 mL 
methanol and 5.0 mL of n-hexane. Colour: Reddish Orange; M. P.: 245-246 oC; Yield 
(%): 98. Anal. Cal. For C15H20N4O4S (FW: 352.41 g mol
-1); C, 51.10; H, 5.60; N, 
15.80; Found: C, 51.15; H, 5.58; N, 15.70 %. 1H NMR (500 MHz, DMSO-d6, Me4Si 
ppm): δ 11.57 (s, N-NH), δ 10.40 (s, OH), δ 8.41 (s, HC=N), δ 8.21 (d, J = 8.55 Hz, 
CS-NH), δ 8.03 (s, aromatic-H), δ 7.54 (s, aromatic-H), δ 3.83 (s, Ph-OCH3), δ 1.86-
1.14 (multiplet, cyclohexyl-H). The 13C NMR (DMSO-d6, Me4Si ppm): δ 175.87 
(C=S), δ 151.51 (C=N), δ 145.55-108.91 (C-aromatic), δ 56.02 (Ph-OCH3), δ 52.94 - 
24.97 (C-cyclohexyl). IR (KBr pellets υmax/cm-1): 3363 υ(NH), 3123 υ(OH), 2934 
υ(CH2, cyclohexyl), 1584 υ(C=N), 1532 υ(C=C, aromatic), 1431 υ(C-H, sp3, bend),  
1249 υ( NO2), 1213 υ(C=S), 1052 υ(C-N), 937 υ(N-N). 
